Pendopharm

Privately held: no public share price

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
PTH1 receptor (PTH replacement)Peptide
Hypoparathyroidism

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
palopegteriparatide · YorvipathPhase 3Hypoparathyroidism
Est. primary completion 2027-08 · NCT07706764 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.